More people with type 2 diabetes achieved blood sugar

0
80


Data introduced at present present extra individuals achieved better therapy satisfaction when switching to once-weekly insulin icodec in ONWARDS 2 trial

Bagsværd, Denmark, Thursday 22 September 2022 – Novo Nordisk at present introduced new information from the section 3a ONWARDS 2 trial, demonstrating that 37% of adults with type 2 diabetes handled with once-weekly insulin icodec achieved an HbA1c <7.0%, with out experiencing extreme or clinically vital hypoglycaemia, in contrast with 27% of these handled with insulin degludec at 26 weeks1. These outcomes have been introduced on the 58th European Association for the Study of Diabetes (EASD) Annual Meeting 20221.

‘Once-weekly insulin would be a remarkable step forward in insulin innovation,’ stated Dr Athena Philis-Tsimikas, Scripps Whittier Diabetes Institute, California, USA, and principal investigator of ONWARDS 2. ‘It could offer people with type 2 diabetes reduced treatment complexity and burden by reducing the number of basal insulin injections from 365 to 52 per year, without compromising management of blood sugar.’

The trial achieved its main endpoint of demonstrating non-inferiority in decreasing HbA1c at week 26 with insulin icodec in contrast with insulin degludec2. From a imply baseline of 8.17% (icodec) and eight.10% (degludec), once-weekly insulin icodec achieved a superior discount in estimated HbA1c of 0.93% in contrast with 0.71% for insulin degludec2.

People with diabetes in ONWARDS 2 reported considerably better satisfaction in favour of once-weekly insulin icodec in contrast with insulin degludec at 26 weeks as assessed by the Diabetes Treatment Satisfaction Questionnaire (DTSQ) 1.

‘We are very pleased to see the promising results from the ONWARDS programme so far,’ stated Martin Holst Lange, Executive Vice President Development, Novo Nordisk. (*2*)

See also  Health Supplement Chain Muscle & Strength India launches store in Imphal

The imply weekly insulin dose was 268 U/week for insulin icodec vs 244 U/week for insulin degludec1. The estimated imply change in physique weight from baseline to week 26 was 1.40 kg for insulin icodec in contrast with –0.30 kg for insulin degludec1.

In the trial, once-weekly insulin icodec appeared to have a secure and well-tolerated profile. There was lower than 1 hypoglycaemic occasion per patient-year uncovered for insulin icodec and insulin degludec (0.73 occasions and 0.27 occasions per patient-year uncovered, respectively, with no statistically vital distinction between arms). As beforehand reported, no extreme hypoglycaemia occasions have been noticed for people handled with insulin icodec1.

For extra information and media supplies from Novo Nordisk at EASD 2022, please go to: https://www.novonordisk.com/news-and-media/e-press-room.html?cid=nnref-1624925851

About insulin icodec
Insulin icodec is a novel once-weekly basal insulin analogue designed to cowl the basal insulin necessities for a full week with a single subcutaneous injection. Currently, the basal insulin merchandise with the longest period are injected as soon as each day1. Insulin icodec is presently going by way of section 3 scientific improvement.

About the ONWARDS scientific programme
The ONWARDS scientific improvement programme for once-weekly insulin icodec includes six section 3a international scientific trials, together with a trial with real-world parts, involving greater than 4,000 adults with type 1 or type 2 diabetes2. Top-line information for the ONWARDS 1, 2, 3, 4 and 6 trials have now learn out, all assembly their main endpoints2-4.

About ONWARDS 2
ONWARDS 2 trial is a section 3a, 26-week efficacy and security treat-to-target trial investigating once-weekly insulin icodec vs once-daily insulin degludec in 526 people with type 2 diabetes switching from each day insulin5. The main endpoint was to evaluate the change in HbA1c at week 26 with insulin icodec in contrast with insulin degludec2.

See also  Out of 77 Million Diabetics, 25% are Expected to Develop Diabetic Foot Ulcers

About Novo Nordisk
Novo Nordisk is a number one international healthcare firm, based in 1923 and headquartered in Denmark. Our goal is to drive change to defeat diabetes and different critical continual illnesses resembling weight problems and uncommon blood and endocrine issues. We accomplish that by pioneering scientific breakthroughs, increasing entry to our medicines, and dealing to forestall and finally remedy illness. Novo Nordisk employs about 50,800 people in 80 international locations and markets its merchandise in round 170 international locations. For extra info, go to novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.

Further info

_______________________

References
1.      Philis-Tsimikas A, Asong M, Franek E, et al. Once-weekly Insulin Icodec Demonstrated Better Glycaemic Control vs Once-daily Insulin Degludec in Basal Insulin-Treated Type 2 Diabetes. European Association for the Study of Diabetes (EASD) – 58th Annual Meeting; 19–23 September 2022; Stockholm, Sweden.
2.      Novo Nordisk. Company announcement. Once-weekly insulin icodec demonstrates superior discount in HbA1c vs insulin degludec in people with type 2 diabetes in ONWARDS 2 section 3a trial. Available at: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=112839 Last accessed: September 2022.
3.      Novo Nordisk. Company announcement. Novo Nordisk achieves main goals of ONWARDS 1 and 6 trials with once-weekly insulin icodec demonstrating superior discount in HbA1c vs insulin glargine U100 in ONWARDS 1. Available at: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=118349 Last accessed: September 2022.
4.      Novo Nordisk. Company announcement. Novo Nordisk achieves main goals of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior discount in HbA1c vs insulin degludec in ONWARDS 3. Available at: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=127304 Last accessed: September 2022.
5.      ClinicalTrials.gov. A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin (ONWARDS 2). Available at: https://clinicaltrials.gov/ct2/show/NCT04770532 Last accessed: September 2022.

  • PR220922 ONWARDS 2_icodec_EASD
See also  Optinose Announces ReOpen1 Abstract Selected for



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here